Amgen takes PCSK9 contest to court
This article was originally published in Scrip
Executive Summary
The frontrunner in the neck-to-neck race to bring the first PCSK9 inhibitor for high cholesterol to market, Amgen, has filed a patent infringement suit to pull rival Sanofi and its partner Regeneron Pharmaceuticals off the track.